Publishing: September 2021 | Report Code: LS10376 | Available Format: PDF
The global autoimmune treatment market is growing significantly due to increasing incidences of autoimmune diseases, up surging healthcare expenditure, and advancements in the technologies for the development of autoimmune diseases therapeutics. Autoimmune diseases are chronic in nature and do not have permanent treatment. This creates ample growth opportunity for the autoimmune treatment market, to grow at a considerable rate in the coming years. The advanced research and development facilities, and new product developments by the companies are propelling the demand for cost effective treatment of autoimmune diseases.
The abnormal response of immune system leads to autoimmune disorders. Normally, the body’s immune system provides protection against foreign bodies or harmful substances. However, in the autoimmune disorders, the immune system fails to differentiate between a healthy tissue or cell and a harmful substance (antigen), and destroys the normal tissues. Autoimmune diseases have high prevalence among female children and women. There are more than 80 prevailing autoimmune diseases. Some of the most common autoimmune disorders include psoriasis, multiple sclerosis, rheumatoid arthritis, type 1 diabetes, systemic lupus erythematosus, inflammatory bowel disease, and Addison’s disease.
Based on applications, the autoimmune treatment market can be categorized as type 1 diabetes, inflammatory bowel disease, multiple sclerosis, systemic lupus erythematosus, psoriasis, rheumatoid arthritis, thyroid disease, and others. Rheumatoid arthritis leads the global autoimmune treatment market, due to high prevalence of rheumatoid arthritis worldwide.
Based on technology, the autoimmune treatment market is segmented as bridge therapy, phototherapy, topical therapy, fecal bacteriotherapy, recombinant technology, diseases-modifying antirheumatic drugs, helminthic therapy, and hematopoietic stem cell transplantation. And based on product types, the autoimmune treatment market can be categorized as diagnostic equipment, drugs, therapeutic equipment, and other products. The drugs category leads the global autoimmune treatment market, in terms of revenue. Drugs are further classified as methotrexate, non-steroidal anti-inflammatory drugs, corticosteroids, glucocorticoids, 5-aminosalicylic acid, and others.
Some of the factors driving the growth of the autoimmune treatment market are aging population, high incidences of autoimmune diseases, and increasing healthcare expenditure. In addition, the major pharmaceutical companies are investing huge amount in the R&D of drugs for the treatment of autoimmune diseases, which in turn is driving the growth of the global autoimmune treatment market. However, the high cost and side effect associated with drugs, lack of standardized treatment procedure, and low insurance coverage for autoimmune diseases are some of the factors restraining the growth of the global autoimmune treatment market to some extent.
Geographically, North America leads the global autoimmune treatment market, due to aging population, high incidences of autoimmune diseases, increased healthcare expenditure, and excessive R&D investment for the development of drugs for autoimmune diseases. Asia-Pacific is the fastest growing region in the global autoimmune treatment market. The major reasons for the fastest growth in the region are increasing healthcare expenditure and improving healthcare infrastructure. Moreover, the autoimmune treatment market is growing, due to increasing disposable income and large population suffering from autoimmune diseases in the emerging countries, such as India and China.
Some of the major players operating in the global autoimmune treatment market are Abott, Bristol-Myers Squibb Company, Amgen Inc., Pfizer Inc., Bayer AG, F. Hoffmann-La Roche AG, Eli Lilly and Company, Novartis AG, Johnson & Johnson Services Inc., Merck & Co. Inc., Sanofi, GlaxoSmithKline PLC, Biogen, Boehringer Ingelheim GmbH, AstraZeneca PLC, and Astellas Pharma Inc.
Get a bespoke market intelligence solution
Our dedication to providing the most-accurate market information has earned us verification by Dun & Bradstreet (D&B). We strive for quality checking of the highest level to enable data-driven decision making for you
Our insights into the minutest levels of the markets, including the latest trends and competitive landscape, give you all the answers you need to take your business to new heights
With 24/7 research support, we ensure that the wheels of your business never stop turning. Don’t let time stand in your way. Get all your queries answered with a simple phone call or email, as and when required
We take a cautious approach to protecting your personal and confidential information. Trust is the strongest bond that connects us and our clients, and trust we build by complying with all international and domestic data protection and privacy laws